MedTrace Logo

Arginase Inhibition in Ischemia-reperfusion Injury

NCT02009527 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-04-20

No results posted yet for this study

Summary

The present project is designed to test the hypothesis that arginase contributes to endothelial dysfunction induced by ischemia-reperfusion in patients with coronary artery disease.

Conditions

Interventions

DRUG

N-hydroxy-nor-arginine

DRUG

NaCl

Sponsors & Collaborators

Principal Investigators

  • John Pernow, MD, PhD · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-04-30
Completion
2013-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02009527 on ClinicalTrials.gov